Media stories about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.9085133570589 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Achillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.16 Per Share (americanbankingnews.com)
- Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost (zacks.com)
- Form 8-K ACHILLION PHARMACEUTICAL For: Feb 22 (streetinsider.com)
- Was Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn? (finance.yahoo.com)
- Achillion Pharmaceuticals (ACHN) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS (americanbankingnews.com)
A number of analysts recently weighed in on ACHN shares. BidaskClub cut shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 13th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Monday, November 13th. Leerink Swann reaffirmed a “buy” rating and set a $5.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. Finally, B. Riley started coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They set a “neutral” rating and a $3.50 price target for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $4.89.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter in the prior year, the firm earned ($0.03) EPS. equities analysts anticipate that Achillion Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.